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Socie ty (ASAS) criteria for axial and peripheral SpA.
Estimates were computed as weighted proportions con-
sidering the study design. Logistic regressions were
used to compare AS/PsA subjects with other RMD and
the adult Portuguese population without rheumatic di -
seases. 
Results: Prevalence rate of SpA was of 1.6% (95% CI
1.2% to 2.1%). Subjects with AS or PsA had worse QoL,
reflected by EQ5D score when compared with the adult
Portuguese population without rheumatic diseases 
(b=- 0.08; p=0.031). AS and PsA also had worse QoL
when compared with participants with other RMD 
(b=-0.22; p>0.001). AS and in comparison to patients
with other RMD, PsA subjects retired early due to their
illness (OR=4.95; 95% CI 1.54% to 15.93%). A signif-
icant proportion of patients with SpA (13.6%) referred
absenteeism in the previous 12 months to the inter-
view. 
Conclusions: AS and PsA were found to be associated
with poor QoL and a high rate of disease-related early
retirement, emphasizing the burden of such rheuma tic
conditions in Portugal.
Keywords: Spondylarthropathies; Absenteeism; Pso-
riatic arthritis; Ankylosing spondylitis; Health-related
quality of life.
IntroductIon
Rheumatic and musculoskeletal diseases (RMD) are
prevalent and leading causes of disability, which results
in greater consumption of healthcare and social re-
sources. The prevalence of RMD has been determined
in several countries, but epidemiological data in Por-
tugal is scarce1-3.
Among RMD, spondyloarthritis (SpA) is a group of
several related but phenotypically distinct disorders. It
includes psoriatic arthritis (PsA), arthritis related to in-
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AbstrAct 
Introduction: Psoriatic arthritis (PsA) and ankylosing
spondylitis (AS) are chronic disorders that significant-
ly impact patients’ quality of life (QoL), health care sys-
tems and society. There is very limited data on the epi-
demiology and the impact of PsA and AS in Portugal,
so in this study we aim to: 1) estimate the prevalence
of PsA and AS in the adult Portuguese population; 2)
compare health-related quality of life (QoL) of PsA and
AS with the one of other rheumatic and musculoskele-
tal diseases (RMD) and with subjects with no rheuma -
tic diseases; 3) compare early retirement and producti -
vity loss among PsA and AS with other RMD.
Methods: We used data from EpiReumaPt, a popula-
tion-based survey, conducted from 2011 to 2013, in
which 10661 subjects, over 18 years old, were screened
for RMD. Spondyloarthritis (SpA) was defined by a
posi tive expert opinion combined with the fulfillment
of the Assessment of Spondyloarthritis International
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flammatory bowel disease, reactive arthritis, a sub-
group of juvenile idiopathic arthritis, ankylosing
spondylitis (AS) and undifferentiated SpA. PsA and AS
are chro nic inflammatory disorders4 that significantly
impact patients’ quality of life (QoL)5-7, health care sys-
tems and society8-13. In the group of SpA, AS is the most
common subtype14. It predominantly affects young
people, who generally present at around 26 years of
age6. Men are more often affected than women, with a
ratio of roughly 2 to 115. Overall, the prevalence of AS
is between 0.1% and 1.4%, with most of these data
coming from Europe6. PsA affects between 0.04% and
1% of the general population and patients are typical-
ly aged 30−55 years at disease presentation16. Fur-
thermore, PsA is equally prevalent in men and wom-
en17.
There is very limited data on the epidemiology and
the impact of PsA and AS in Portugal. For this reason,
it is fundamental to estimate the prevalence and impact
of these diseases in Portugal. PAASPORT is a sub ana -
lysis of EpiReumaPt that aimed to estimate the preva-
lence and impact of PsA and AS in the Portuguese ter-
ritory. The primary objective of this work 1) was to
estimate the prevalence of PsA and AS in Portugal and
to characte rize the national PsA and AS population.
Other goals of this study included: 2) comparison of
health-rela ted quality of life (QoL) of PsA and AS with
other rheumatic and musculoskeletal diseases (RMD)
and with subjects without rheumatic diseases; and 3)
comparison of early retirement and productivity loss
among PsA and AS with other RMD.
Methods
For this study we used data from EpiReumaPt, a large
cross-sectional, population-based, observational study
of RMD. Participants were selected through a process
of multistage random sampling. The sample was strat-
ified according to the Portuguese Nomenclature of Ter-
ritorial Units for Statistics (NUTS II; seven territorial
units: Norte, Centro, Alentejo, Algarve, Lisboa e Vale
do Tejo, Madeira and Azores) and the size of the popu -
lation (<2000; 2000–9999; 10 000–19 999; 20
000–99 999; and ≥100 000 inhabitants). The study
methodology has been extensively described else-
where19,20.
EpiReumaPt study population was composed by
non-institutionalized adults (≥18 years-old) living in
private households in Portugal (Mainland and the Is-
lands - Madeira and the Azores). Exclusion criteria
were: residents in hospitals, nursing homes, military
institutions or prisons, and individuals unable to speak
Portuguese or unable to complete the questionnaire,
despite being aided4.
EpiReumaPt enrolled 10,661 subjects and was de-
signed to primarily estimate the prevalence of RMD. In
order to provide a comprehensive understanding of
the burden of RMD, this survey also had as secondary
aims: the evaluation of quality of life, physical function,
mental health, work status and healthcare resource
consumption, with the purpose of identifying differ-
ences in these health and other outcomes between in-
dividuals with and without RMD19.
Data collection of EpiReumaPt included two diffe -
rent phases: Phase 1 – face-to-face interviews con-
ducted by a team of trained interviewers (non-physi-
cians) through door-to-door visits, and Phase 2 –
clinical observations with physical examination per-
formed by rheumatologists and conducted in all par-
ticipants that were identified as potentially having an
RMD by a screening questionnaire applied at Phase 1,
and in 20% of asymptomatic individuals. All proce-
dures of EpiReumaPt, including Phase 1 and 2, oc-
curred between September 2011 and December 2013
(Figure 1). 
EpiReumaPt study protocol was approved by Por-
tuguese Data Protection Authority, Administração Re-
gional de Saúde do Norte I.P, Administração Regional de
Saúde de Lisboa e Vale do Tejo and by NOVA Medical
School, Universidade NOVA de Lisboa Ethics Commit-
tees. A written informed consent was obtained from
each patient.
In this study we focused on patients with a diagno-
sis of PsA or AS. SpA diagnosis was established ac-
cording to the Assessment of SpondyloArthritis Inter-
national Society (ASAS) criteria for axial and peripheral
SpA21-23. SpA subtypes (AS, PsA and other SpA) were
defined by expert opinion (clinical decision made by
a rheumatologist).
stAtIstIcAl Methods
Details regarding sample size calculation of
EpiReumaPt were previously described elsewhere4,18,19.
Prevalence estimates and confidence intervals were
computed considering the sampling design. Descripti -
ve data for each categorical variable was presented as
the absolute frequency and the correspondent pro-
portion adjusted for study design. The same adjust-
ment was performed for the mean and standard devia -
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Other RMD were defined as individuals who have an
RMD other than a SpA and included subjects with
hand, knee and hip osteoarthritis (OA), low back pain
(LBP), rheumatoid arthritis (RA), fibromyalgia (FM),
gout, periarticular diseases (PD), systemic lupus ery-
thematosus (SLE), polymyalgia rheumatica (PMR) and
osteoporosis (OP)19.
results
spA preVAlence
The prevalence of total SpA (which includes AS, PsA
and other SpA) was 1.6% (CI 1.2%-2.1%). AS accoun -
ted for 29.6% of cases and PsA for 18.7% – corres -
ponding to a prevalence rate of 0.5% (95% CI 0.3% to
0.7%) and 0.3% (95% CI 0.1% to 0.5%), respectively.
In absolute numbers, there were 32 cases of AS and 20
PsA patients. Moreover, the relative frequency of AS
and PsA among RMD patients was 0.9% (CI
0.5%;1.2%) and 0.5% (CI 0.2%;0.9%), respectively.
Prevalence of SpA was also estimated according to
NUTS II classification and the North Region of Portu-
gal was found to have a lower prevalence of all types of
SpA (1.3% (CI: 0.7%;2.0%)).
spA populAtIon chArActerIstIcs
Table I shows the clinical and sociodemographic char-
acteristics of Portuguese subjects with SpA (total, AS,
PsA and other SpA). The majority of subjects had a nor-
mal BMI, but did not practice physical exercise. Re-
garding lifestyle habits, most patients did not smoke
and had an occasional intake of alcohol.
In EpiReumaPt, rheumatologists diagnosed 68 new
SpA cases. Definitive diagnosis of SpA was made more
frequently in younger patients, with a mean age at
diagno sis of 42.2±17.2 years. SpA patients had a mean
disease duration of 1.39±7.12 years, which was slight-
ly higher in the AS subtype (3.77±14.13) (Table I).
Disea se activity was measured through the BASDAI in-
dex. Table II describes the BASDAI index for each type
of SpA. When we analyzed the mean BASDAI score in
the AS/PsA subjects with RMD related retirement
(6.77±1,41 and 5.27±0,72, respectively), we found
that it was higher than the mean overall BASDAI score
of the disease (5.73±3.40 and 4.63±1,84, respectively). 
coMorbIdItIes In spA subjects
Self-reported comorbidities of Portuguese patients with
SpA were also analyzed. Subjects were asked about
tion (SD) of each continuous variable. Regarding SpA
population characteristics, SF-36 scores were calculat-
ed according to Pedro Lopes Ferreira et al24. Linear or
multinomial logistic regressions were used to compare
subjects with AS or PsA, other RMD and subjects with-
out rheumatic diseases. The adjusted analysis was
based on models of the same type, but wherein the sex,
age and NUTS II were included as covariates. The cut-
off value for significance was considered to be p<0.05.
All analyses were weighted and performed using Stata
Statistical Software: Release 12.
VArIAbles defInItIons
The Health Assessment Questionnaire (HAQ) score
was categorized as: "mild to moderate difficulty" (score
<0.8); "moderate to severe disability" (0.8 ≤ score <1.2)
and "severe to very severe disability" (score ≥ 1.2)25.The
proportion of individuals with changes in their profes-
sional situation due to RMD was calculated (all indi-
viduals with information on their employment status
were taken as reference population). Subjects with ear-
ly retirement due to RMD were identified as those who
have retired due RMD and have their lower retirement
age to under 65 years (data from the 1st Phase); the pro-
portion of subjects with early retirement due to RMD
was calculated taking as reference population all indi-
viduals with information about their employment sta-
tus, retired or not. Information about absenteeism and
retirement was self-reported. To calculate the age at di-
agnosis and time since diagnosis, it was assumed that
the diagnosis occurred at query time, for indivi duals
without previous diagnosis, or the date of prior diagno -
sis, when available; when only the year of dia gnosis
was available, it was assumed that diagnosis was made
on June 30 (half year). The time from first symptom to
diagnosis was calculated as the difference between the
diagnostic date (see previous point) and the date of the
first symptom, considered as the date of the symptom
that occurred first; for this, we considered the three
dates of symptoms available on SpA screening (medi-
cal appointment): start date of back pain, inflammato-
ry joint pain and other symptoms. Finally, working age
population was defined as those aged 15 to 64 years.
Body mass index (BMI) categories were defined ac-
cording to the World Health Organization criteria26:
underweight (BMI < 18.5 kg/m2), normal weight (BMI
between 18.5 and 24.9kg/m2), pre-obesity (BMI be-
tween 25.0 and 29.9 kg/m2), obese class I (BMI be-
tween 30.0 and 34.9 kg/m2), class II (BMI between 35.0
and 39.9 kg/m2) and class III (BMI ≥ 40.0 kg/m2
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tAble I. socIodeMogrAphIc And clInIcAl chArActerIstIcs of populAtIon wIth spA (totAl), As, psA,
other spA, other rMd And subjects wIthout rheuMAtIc dIseAses 
Spondylo-
arthritis Ankylosing  Psoriatic Other Other No rheumatic 
(total) Spondylitis Arthritis SpA RMD diseases
n=92 n=32 n=20 n=40 n=3106 n=679
Female gender 59 (63.91%) 22 (77.91%) 10 (41.88%) 27 (63.90%) 2205 (59.58%) 366 (53.90%)
Age (mean ± Sd) 43.81 ± 17.77 43.27 ±23.19 51.51 ± 15.89 41.33 ± 13.91 53.17 ± 20.90 38.08 ± 9.58
Age group, n (%)
18-34 y 18 (34.04%) 9 (38.79%) 1 (15.21%) 8 (38.15%) 159 (18.09%) 171 (25.18%)
35-54 y 44 (41.66%) 13 (37.35%) 9 (37.66%) 22 (45.57%) 953 (33.12%) 315 (46.39%)
55-64 y 18 (14.81%) 3 (7.24%) 8 (37.19%) 7 (11.02%) 791 (18.41%) 89 (13.11%)
65-74 y 8 (5.97%) 5 (10.99%) 0 (0.00%) 3 (5.27%) 743 (17.61%) 72 (10.60%)
≥75 y 4 (3.52%) 2 (5.62%) 2 (9.93%) 0 (0.00%) 460 (12.77%) 32 (4.71%)
Years of education 
(mean ± Sd) 8.76 ± 4.46 9.12 ± 4.65 5.74 ± 3.96 9.65 ± 3.78 7.43 ± 4.73 9.79 ± 2.20
Education level, n(%)
> 12 years 18 (20.87%) 5 (12.31%) 1 (3.72%) 12 (31.97%) 336 (14.59%) 207 (30.53%)
10-12 years 20 (26.29%) 9 (43.76%) 2 (16.10%) 9 (19.99%) 376 (16.52%) 138 (20.35%)
5-9 years 22 (25.82%) 8 (22.62%) 5 (19.06%) 9 (30.10%) 615 (25.39%) 179 (26.40%)
0-4 years 32 (27.03%) 10 (21.31%) 12 (61.12%) 10 (17.94%) 1758 (43.50%) 154 (22.71%)
Employment status, n(%)
Employed full-time 43 (49.17%) 13 (34.02%) 9 (50.87%) 21 (57.21%) 851 (35.29%) 327 (48.23%)
Employed part-time 5 (4.16%) 1 (1.50%) 1 (4.23%) 3 (5.65%) 87 (3.52%) 25 (3.69%)
Domestic worker 4 (2.82%) 0 (0.00%) 1 (0.55%) 3 (5.25%) 249 (4.69%) 33 (4.87%)
Unemployed 14 (23.19%) 7 (32.71%) 1 (15.79%) 6 (20.43%) 283 (13.04%) 93 (13.72%)
Retired 23 (17.39%) 9 (22.07%) 8 (28.57%) 6 (10.67%) 1471 (37.71%) 142 (20.94%)
Student 1 (2.67%) 1 (9.05%) 0 (0.00%) 0 (0.00%) 25 (2.88%) 32 (4.72%)
Temporally work 1 (0.19%) 1 (0.65%) 0 (0.00%) 0 (0.00%) 70 (1.74%) 9 (1.33%)
disabled
Other 1 (0.41%) 0 (0.00%) 0 (0.00%) 1 (0.79%) 33 (1.12%) 17 (2.51%)
Marital status, n(%)
Single 13 (25.70%) 5 (31.22%) 1 (3.72%) 7 (30.51%) 275 (20.00%) 168 (24.74%)
Married 63 (61.14%) 22 (56.51%) 16 (90.04%) 25 (53.32%) 2009 (57.17%) 388 (57.14%)
Divorced 6 (5.62%) 2 (5.69%) 0 (0.00%) 4 (7.61%) 251 (7.93%) 53 (7.81%)
Widow(er) 7 (4.77%) 2 (5.93%) 3 (6.23%) 2 (3.58%) 506 (11.81%) 37 (5.45%)
Consensual union 3 (2.77%) 1 (0.65%) 0 (0.00%) 2 (4.98%) 65 (3.03%) 31 (4.57%)
Body Mass Index 26.01 ± 5.38 26.84 ± 5.38 25.37 ± 5.32 25.84 ± 5.18 26.73 ± 6.03 25.01 ± 2.57
(kg/m2) (mean ± sd)
Body Mass Index 
(kg/m2), n(%)
Underweight 2 (2.80%) 0 (0.00%) 0 (0.00%) 2 (5.25%) 34 (1.42%) 10 (1.51%)
Normal 39 (45.52%) 11 (37.68%) 7 (53.36%) 21 (46.57%) 890 (37.54%) 305 (45.93%)
Overweight 32 (30.19%) 15 (40.28%) 9 (32.14%) 8 (24.39%) 1198 (40.32%) 255 (38.40%)
Obese 16 (21.48%) 4 (22.04%) 4 (14.50%) 8 (23.79%) 814 (20.71%) 94 (14.16%)
Smoking habits, n(%)
Smoker 16 (21.49%) 7 (18.77%) 1 (4.22%) 8 (29.30%) 421 (20.46%) 156 (22.97%)
Non-smoker 76 (78.51%) 25 (81.23%) 19 (95.78%) 32 (70.70%) 2683 (79.54%) 523 (77.03%)
continues on the next page
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their comorbidities in EpiReumaPt’s 1st phase (Table
III). SpA population had a high prevalence of cardio-
vascular risk factors, namely high blood pressure
(20.79%) and high cholesterol level (30.41%). In par-
ticular, PsA patients had a higher prevalence of such
risk factors, with 35.99% of patients having high blood
pressure and more than 45% reporting high choles-
terol levels. Gastrointestinal disease was also a preva-
lent comorbidity in SpA (23.43%). In addition, 13.13%
of SpA patients reported a mental disease (Table III). 
the burden of spA - coMpArIson of spA 
subtypes
In brief, AS patients had worse quality of life reflected
by EQ5D score (EQ5D scoreAS = 0.66±0.35; EQ5D
scorePsA = 0.71 ± 0.25; EQ5D scoreother SpA = 0.74 ± 0.24)
and also among SF-36 dimensions scores, than other
SpA patients. Function is also worse among these pa-
tients (HAQ scoreAS = 0.56 ± 0.95; HAQ scorePsA = 0.48
± 0.75; HAQ scoreother PsA = 0.32 ± 0.54). Although they
have a higher HAQ score, the majority of them report-
ed mild to moderate difficulty (72.00%). Patients with
AS and those with PsA have more anxiety symptoms
(mean HADS Anxiety score = 8.31 ± 6.26 and 8.60 ±
5.26, respectively) and depression (mean HADS De-
pression score = 6.34 ± 6.51 and 4.98 ± 4.35, respec-
tively), than those with other SpA.
the burden of spA - coMpArIson between
psA/As pAtIents, pAtIents wIth other rMd
And subjects wIth no rheuMAtIc dIseAses 
When comparing subjects with AS or PsA with other
RMD, AS/PsA patients had a significantly worse EQ5D
score (b=- 0.08; p=0.031) and worse SF-36 score
among the following dimensions: bodily pain 
(b=-13.83; p=0.001), general health (b=-12.27;
p<0.001), vitality (b=-10.68; p=0.011), social function
(b=-13.11; p=0.001), emotional role (b=-19.41;
p=0.019) and mental health (b=-10.74; p=0.024)
(Table IVa). AS/PsA patients also had worse EQ5D score
(b=-0.22; p<0.001) and worse SF-36 in 8 of the 9 di-
mensions evaluated when compared with subjects
without rheumatic diseases (Table IVb). Additionally,
significant differences were found regarding anxiety
symptoms, which were higher in AS and PsA, com-
pared with other RMD (OR=2.71; p=0.033), and with
subjects without rheumatic diseases (OR=8.14;
p=0.001). Subjects with other RMD or no rheumatic
Sd: standard deviation; SpA: spondyloarthritis; RMD: rheumatic and musculoskeletal diseases; NA: not applicable; n: number.
tAble I. contInuAtIon
Spondylo-
arthritis Ankylosing  Psoriatic Other Other No rheumatic 
(total) Spondylitis Arthritis SpA RMD diseases
n=92 n=32 n=20 n=40 n=3106 n=679
Alcohol intake, n(%)
Daily/ocasional 
intake 50 (61.23%) 17 (57.42%) 10 (68.20%) 23 (60.88%) 1608 (61.43%) 420 (61.86%)
Never 42 (38.77%) 15 (42.58%) 10 (31.80%) 17 (39.12%) 1493 (38.57%) 259 (38.14%)
Regular physical, n(%) 
Exercise
Yes 27 (26.31%) 11 (29.40%) 5 (28.49%) 11 (23.76%) 902 (33.17%) 253 (37.32%)
No 65 (73.65%) 21 (70.60% 15 (71.51%) 29 (76.24%) 2202 (66.83%) 425 (62.68%)
Age at time of 42.16 ± 17.23 37.55 ± 22.47 50.76 ± 15.75 41.32 ± 13.66 No NA
diagnosis, in years observations
(mean ± sd)
Time since diagnosis, 1.39 ± 7.12 3.77 ± 14.13 0.80 ± 2.83 0.49 ± 2.74 No NA
in years (mean ± sd) observations
Time since 1st symptom 11.40 ± 12.75 11.34 ± 15.10 15.60 ± 12.67 10.11 ± 10.84 No NA
to diagnosis, in years observations
(mean ± sd)
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diseases reported less depression (b =1.90; p=0.016
and b =2.93; p>0.001, respectively) when compared
with AS/PsA patients. Concerning physical function,
we found that AS/PsA patients had a higher proportion
of moderate (RRR=2.44; p=0.045) and severe disabil-
ity (RRR=2.97; p=0.008) than subjects with another
RMD and those with no rheumatic diseases (moderate
disability: RRR=4.85; p=0.041 and severe disability:
RRR=17.05; p<0.001) (Table IVa and IVb). 
eMployMent stAtus And AbsenteeIsM In spA
Most patients with SpA were employed (Table I). How-
ever, a significant proportion of patients (13.6%) re-
ferred absenteeism in the last 12 months. Patients with
PsA showed more retirement (18.16%) and more ear-
ly retirement (19.54%) due to disease when compared
with other SpA (1.89% and 1.97%, respectively).
When we analyzed the mean HAQ score in SpA 
subjects that mentioned absenteeism in the previous
12 months (0.81 ± 0.62), we found that it was higher
than the mean HAQ score of the disease (0.42 ± 0.72).
Moreover, the mean HAQ score in patients with dis-
ease-related early retirement (0.88 ± 1.38) was also
higher than the mean HAQ score of the disease (0.42
± 0.72).
coMpArIson between psA/As pAtIents And
pAtIents wIth other rMd regArdIng the 
eMployMent stAtus And AbsenteeIsM
When we compared subjects with AS or PsA with pa-
tients with another RMD diagnosis, we found a signif-
icantly difference in early retirement related to disease
(OR=4.95; p=0.007) (Table V). 
heAlth resources consuMptIon In spA 
Among SpA patients, individuals with AS showed high-
er consumption of health resources than patients with
PsA. Nonetheless, these findings have some limitations,
since they represent a very small sample size. No dif-
ferences were found regarding healthcare consumption
resources between AS/PsA and other RMD.
dIscussIon
In this analysis, using a population-based epidemio-
logical study in Portugal, we have characterized the
Portuguese SpA population and its subtypes, namely
AS and PsA. In the EpiReumaPt study we have used
the ASAS criteria for SpA27 and found a prevalence of
1.6%; Norte Region had the lower prevalence of all
tAble II. dIseAse ActIVIty (bAsdAI) In subjects wIth spA, (totAl); As, psA And other spA
Spondyloarthritis Ankylosing Psoriatic 
(total) spondylitis arthritis Other SpA
n=92 n=32 n=20 n=40
Disease activity - BASDAI score 5.87 ± 3.48 5.73 ± 3.40 4.63 ± 1.84 6.31 ± 3.57
(mean ± sd) - total population
RMD related work absenteeism, 6.76 ± 1.84 5.61 ± 0.18 6.8 ± 0 7.23 ± 1.81
in the last 12 months
Non-RMD related work absenteeism, 5.74 ± 3.67 5.74 ± 3.67 4.60 ± 1.76 6.13 ± 3.86
in the last 12 months
RMD related retirement 5.73 ± 1.43 6.77 ± 1.41 5.27 ± 0.72 NA
Non-RMD related retirement 5.91 ± 3.54 5.71 ± 3.49 4.57 ± 1.95 6.33 ± 3.61
Disease activity - Active (BASDAI 55 20 10 25 
score ≥ 4) - total population (75.90%) (67.09%) (73.58%) (82.15%)
RMD related work absenteeism, 6 (90.13%) 2 (100.00%) 1 (100.00%) 3 (85.88%)
in the last 12 months
Non-RMD related work absenteeism, 49 (73.87%) 18 (63.10%) 9 (73.21%) 22 (81.40%)
in the last 12 months
RMD related retirement 5 (100.00%) 2 (100.00%) 3 (100.00%) 0 (0.00%)
Non-RMD related retirement 45 (74.99%) 15 (64.06%) 7 (73.75%) 23 (81.37%)
Sd: standard deviation; SpA: spondyloarthritis; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index
ÓRGÃO OFICIAL DA SOCIEDADE PORTUGUESA DE REUMATOLOGIA
260
the BuRden of spa: a compaRative population-Based study
Sd: standard deviation; SpA: Spondyloarthritis; RMD: rheumatic and musculoskeletal diseases 
tAble III. coMorbIdItIes And heAlthcAre resources consuMptIon AMong subjects wIth spA (totAl),
As, psA, other spA, other rMd And subjects wIthout rheuMAtIc dIseAses  
Spondylo-
arthritis Ankylosing  Psoriatic Other Other No rheumatic 
(total) Spondylitis Arthritis SpA RMD diseases
n=92 n=32 n=20 n=40 n=2783 n=630
Number of 1.64 ± 1.98 1.74 ± 2.32 1.66 ± 1.66 1.58 ± 1.87 1.96 ± 2.22 0.96 ± 0.71
comorbidities 
(self-reported) 
(mean ± sd)
Number of comorbidities 
(self-reported), n(%)
0 21 (31.83%) 8 (33.34%) 4 (25.24%) 9 (33.40%) 444 (15.95%) 221 (35.08%)
1 21 (22.25%) 6 (21.47%) 5 (25.38%) 10 (21.53%) 583 (20.95%) 179 (28.41%)
2 18 (19.90%) 4 (15.48%) 4 (12.78%) 10 (24.69%) 591 (21.24%) 109 (17.30%)
≥ 3 25 (26.02%) 9 (29.71%) 6 (36.60%) 10 (20.37%) 1165 (41.86%) 121 (19.21%)
Comorbidities 
(self-reported), n(%)
High blood pressure 20 (20.79%) 7 (20.56%) 8 (35.99%) 5 (15.40%) 1350 (33.40%) 158 (23.51%)
Diabetes 4 (4.03%) 3 (9.93%) 0 (0.00%) 1 (2.12%) 472 (15.35%) 63 (9.36%)
High cholesterol level 31 (30.41%) 12 (31.49%) 9 (45.84%) 10 (24.21%) 1344 (43.85%) 181 (27.06%)
Pulmonary disease 11 (10.81%) 6 (17.90%) 1 (9.76%) 4 (7.13%) 243 (7.87%) 41 (6.07%)
Cardiac Disease 11 (7.93%) 5 (11.73%) 3 (6.81%) 3 (6.22%) 574 (18.70%) 56 (8.33%)
Gastrointestinal 23 (23.43%) 5 (14.80%) 4 (21.80%) 14 (29.03%) 806 (26.23%) 78 (11.61%)
disease
Allergy 23 (21.93%) 10 (28.88%) 4 (12.53%) 9 (21.37%) 817 (26.51%) 145 (21.61%)
Mental disease 14 (13.13%) 2 (8.44%) 4 (18.07%) 8 (13.93%) 679 (21.98%) 71 (10.52%)
Neoplasic disease 3 (3.08%) 2 (5.93%) 0 (0.00%) 1 (2.57%) 169 (5.47%) 36 (5.33%)
Thyroid and 
parathyroid disease 14 (12.64%) 5 (14.09%) 1 (0.89%) 8 (16.08%) 419 (13.66%) 51 (7.56%)
Hyperuricemia 5 (7.26%) 2 (7.92%) 1 (15.79%) 2 (3.78%) 303 (9.97%) 24 (3.60%)
Renal colic 11 (11.66%) 5 (15.72%) 0 (0.00%) 6 (13.38%) 377 (12.27%) 38 (5.66%)
Was hospitalized in the 13 (11.32%) 5 (9.43%) 1 (4.12%) 7 (15.02%) 311 (10.02%) 53 (7.81%)
last 12 months, n(%)
Was hospitalized due 2 (1.19%) 1 (0.65%) 0 (0.00%) 1 (1.94%) 46 (1.48%) 1 (0.15%)
to RMD, n(%)
Had home care in the 2 (2.11%) 1 (3.45%) 0 (0.00%) 1 (2.12%) 98 (3.16%) 5 (0.74%)
last 12 months, n(%)
types of SpA. Global prevalence values for SpA, which
were calculated before the introduction of the ASAS
criteria, were reported to be ≈ 1%28, but ranging from
0.001% in Japan29 to 2.5% in Northern Artic Natives30.
In fact, the new ASAS classification criteria for axial
SpA cover a larger disease spectrum, from no structural
damage to advanced disease. When considering AS
prevalence in particular, our results indicate a slightly
lower prevalence than that described in other studies31-33.
PsA prevalence was similar to that previously reported
for the U.S. population (between 0.3% and 1%)16. We
would like to emphasize the 68 new SpA diagnoses
among a total of 92, suggesting that more than 70% of
SpA cases in the Portuguese population are not diag-
nosed. This is a disturbing finding and, whether it is
due to deficient referral to a rheumatology specialist or
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to an inadequate access to a rheumatology centre,
should be clarified and prompt political intervention.
Our study showed that a definitive diagnosis of SpA
was made more frequently in the younger population.
However, the age at diagnosis presented is more than
10 years older than that previously described6. This
could be due to delayed diagnosis, but there is some
eviden ce that late-onset forms of SpA may become
more common because of longer life expectancy34.
Also, as described in other studies35, PsA patients
showed an older age at diagnosis when compared with
AS patients.
The fact that most subjects did not practice physical
exercise is a particularly alarming finding, especially
considering the high prevalence of cardiovascular risk
factors reported. Physical exercise has been shown to
improve disease activity, symptoms, functional capa -
city, cardiorespiratory function and QoL, and it has
been suggested that it could prevent the development
of dama ge, with a synergistic effect with drug treat-
ment36,37. The importance of exercise in SpA has led to
its inclusion in the consensus for the management of
SpA by diverse international organisms38-40. It is well
known that patients with inflammatory joint diseases
have increased cardiovascular disease risk, compared
with the general population. Previous data indicate that
cardiovascular burden of patients with SpA, PsA41 and
AS42,43 is increased compared with the general popula-
tion. These patients have a high prevalence of tradi-
tional risk factors, but there seems to be an additional
disease-related risk for increased cardiovascular mor-
bidity and mortality41,44.
We also aimed to compare health related QoL of PsA
and AS with the general population and other RMD.
Our results indicate that patients with AS and PsA have
a worse QoL and function than subjects without
rheumatic diseases or with other RMD. Previous stu dies
found that patients with PsA have significantly poorer
health-related QoL than the general population45. PsA
is associated with worse QoL and patients with PsA
have worse functional status and greater disability than
those with psoriasis alone45. The presence of concurrent
psoriasis can confound the impact of PsA, because pso-
riasis is also associated with a high burden of illness45.
Further, the impact of psoriasis is more than cosmetic,
with suicidal ideation being reported in approximate-
ly 10% of patients aged 18–34 years45. Both cross-sec-
tional and some longitudinal studies have showed that
AS patients’ QoL is diminished compared with the gen-
eral population, although similar to the QoL of patients
with other RMD46. In 2014, Ovayolu et al. reported that
physical and mental QoL were remarkably impaired in
AS patients, in comparison to healthy subjects47. Our
study revealed higher anxiety and depression in pa-
tients with AS or PsA when compared with the gene ral
population and subjects with other RMD, stressing the
burden of disease, not only on physical dimension, but
also on mental health. Mental disease can contribute to
subjects’ debility along with all other complications as-
sociated with the disease. It seems that, besides all the
new therapeutic strategies, QoL and mental health re-
main worrisome issues.
By definition, SpA is a disease that occurs in young
adults at the peak of their productive lifespan23.More-
over, it is associated with a considerable burden in
terms of restrictions in activities of daily living and in
work productivity, which could ultimately lead to un-
employment48. The reduction in work productivity is
an important component of the indirect costs of SpA.
In our study, although most patients were employed, al-
most 14% reported absenteeism in the last year. In fact,
a recent study found that in Portugal, AS patients lose
a mean of 110 working days per year, with a tremen-
dous economic impact (Coelho P, Espondilite An-
quilosante em Portugal). Patients with AS or PsA
showed more disease-related early retirement than sub-
tAble V. eArly retIreMent AMong subjects wIth spondyloArthrItIs (totAl), AnkylosIng 
spondylItIs, psorIAtIc ArthrItIs, other spA And other rMd
Spondyloarthritis Ankylosing Psoriatic Other
(Total) spondylitis arthritis SpA Other RMD
n=92 n=32 n=20 n=40 n=3,106
RMD related retirement (yes), n(%) 9 (6.47%) 3 (7.08%) 5 (18.16%) 1 (1.89%) 197 (9.34%)
RMD related early retirement (yes), n(%) 8 (5.92%) 2 (4.25%) 5 (19.54%) 1 (1.97%) 181 (9.97%)
SpA: spondyloarthritis; RMD: rheumatic and musculoskeletal diseases
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jects with another RMD. This appears to be related with
disability, since physical function scores were worse in
these patients. Chronic diseases pose serious challenges
to the healthcare system, specifically through the large-
scale consumption of health resources. Regarding the
latter, we didn’t find a difference between AS/PsA pa-
tients and subjects with another RMD, but given the
very small sample size, more research is needed in or-
der to obtain more reliable results.
conclusIons
PAASPORT analysis on EpiReumaPt data enabled the
first population-based evaluation of Portuguese pa-
tients with SpA, namely AS and PsA. Our results em-
phasize the burden of SpA, which was associated with
poor QoL and high early retirement related to disease,
particularly for AS patients. The major physical, men-
tal and socio-economic impact of PsA and AS in Por-
tugal has also been demonstrated.
This study supports the need to adequately diagnose
and treat patients to prevent long-term damage and
early retirement, and the necessity to increase SpA
awareness, making it a strong argument to encourage
policy makers to expand the resources allocated to
RMD diagnosis and treatment.
correspondence to
Joana Ramos Rodrigues
NOVA Medical School, 
Faculdade de Ciências Médicas, Universidade Nova de Lisboa
CEDOC - Campus Sant’Ana Pólo de Investigação, NMS, UNL. 
Edifício Amarelo. Piso 3, Lisboa
E-mail: joanarodrigues_90@hotmail.com
references 
1. Pádua F, Branco J, Queiroz V. Inquérito epidemiológico das
doenças reumáticas numa amostra da população portuguesa
(Resultados Preliminares). Acta Reumatol Port 1991;16:98.
2. Figueirinhas J. Estudo Epidemiológico dos reumatismos. Acta
Reumatol Port 1976;IV:23–56.
3. Figueirinhas J. Alguns dados definitivos obtidos através do re-
cente inquérito epidemiológico de reumatismos. Acta Reuma-
tol Port 1976;IV:373–380.
4. Ramiro S, Canhão H, Branco J. EpiReumaPT Protocol – Por-
tuguese Epidemiologic Study of the Rheumatic Diseases. Acta
Reumatol Port 2010;35:384-390.
5. Stolwijk C, Boonen A, van Tubergen A, Reveille JD. Epidemiol-
ogy of Spondyloarthritis. Rheum Dis Clin North Am
2012;38:441–476.
6. Sieper J, Braun J. Ankylosing spondylitis. Lancet 2007;
369:1379–1390.
7. Gordon K, Ruderman E. Psoriasis and Psoriatic Arthritis: An In-
tegrated Approach. Berlin Heidelberg: Springer-Verlag,
2005;12-21
8. Boonen A. Direct costs of ankylosing spondylitis and its deter-
minants: an analysis among three European countries. Ann
Rheum Dis 2003;62:732–740.
9. Kawalec P, Malinowski K. The indirect costs of psoriatic arthri-
tis: systematic review and meta-analysis. Expert Rev Pharma-
coecon Outcomes Res 2015;15:125–132.
10. Bonafede M, Joseph G, Princic N, Harrison D. Annual acquisi-
tion and administration cost of biologic response modifiers per
patient with rheumatoid arthritis, psoriasis, psoriatic arthritis,
or ankylosing spondylitis. J Med Econ 2013;16:1120–1128.
11. Tsifetaki N, Migkos M, Papagoras C, Voulgari P, Athanasakis K,
Drosos A. Counting Costs under Severe Financial Constraints:
A Cost-of-Illness Analysis of Spondyloarthropathies in a Ter-
tiary Hospital in Greece. J Rheumatol 2015;42:963–967.
12. Gao X, Wendling D, Botteman M, Carter JA, Rao S, Cifaldi M.
Clinical and economic burden of extra-articular manifestations
in ankylosing spondylitis patients treated with anti-tumor
necrosis factor agents. J Med Econ. 2012;15:1054–1063.
13. Miranda L, Negreiro F, Queiroz M, Silva C. RAISE study obser-
vational and cross sectional study to evaluate the actual reality
of the socio-economic impact of ankylosing spondylitis. Acta
Reumatol Port. 2008;33:189–197.
14. Erol K, Gok K, Cengiz G, Kilic G, Kilic E, Ozgocmen S. Extra-
articular manifestations and burden of disease in patients with
radiographic and non-radiographic axial spondyloarthritis. Acta
Reumatol Port 2018;43:32–39.
15. Feldtkeller E, Khan M, van der Heijde D, van der Linden S,
Braun J. Age at disease onset and diagnosis delay in HLA-B27
negative vs. positive patients with ankylosing spondylitis.
Rheumatol Int 2003;23:61–66.
16. Gladman D. Psoriatic arthritis: epidemiology, clinical features,
course, and outcome. Ann Rheum Dis 2005;64:14–7.
17. Ruiz G. Psoriatic arthritis: a clinical entity distinct from psoria-
sis? Psoriatic Arthritis 2012;52:630-638
18. Gouveia N, Rodrigues A, Ramiro S, Machado P, da Costa L,
Mourão A et al. EpiReumaPt: how to perform a national popu-
lation based study - a practical guide. Acta Reumatol Port
2015;40:128–136.
19. Rodrigues A, Gouveia N, da Costa L, Eusébio M, Ramiro S,
Machado P, et al. EpiReumaPt- the study of rheumatic and mus-
culoskeletal diseases in Portugal: a detailed view of the
methodo logy. Acta Reumatol Port 2015;40:110–124.
20. Branco J, Rodrigues A, Gouveia N, et al. Prevalence of rheumat-
ic and musculoskeletal diseases and their impact on health-re-
lated quality of life, physical function and mental health in Por-
tugal: results from EpiReumaPt- a national health survey. RMD
Open 2016;2: e000166. doi:10.1136/rmdopen-2015-000166
21. Rudwaleit M, van der Heijde D, Landewé R et al. New ASAS
classification criteria for peripheral spondyloarthritis. Ann
Rheum Dis 2009;68:127.
22. Rudwaleit M, van der Heijde D, Landewe R, Akkoc N, Brandt
J, Chou CT, et al. The Assessment of SpondyloArthritis inter-
national Society classification criteria for peripheral spondy-
loarthritis and for spondyloarthritis in general. Ann Rheum Dis
2011;70:25–31.
23. Rudwaleit M, van der Heijde D, Landewe R, Listing J, Akkoc N,
Brandt J, et al. The development of Assessment of Spondy-
loArthritis international Society classification criteria for axial
spondyloarthritis (part II): validation and final selection. Ann
Rheum Dis 2009;68:777–783.
ÓRGÃO OFICIAL DA SOCIEDADE PORTUGUESA DE REUMATOLOGIA
265
RodRigues J et al
24. Ferreira P. Criação da versão portuguesa do MOS SF-36. Parte
I – Adaptação cultural e linguística. Acta Med Port 2000;13:55-
-66.
25. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of pa-
tient outcome in arthritis. Arthritis Rheum 1980;23:137–145.
26. World Health Organization: Obesity: Preventing and Managing
the Global Epidemic. Report of a WHO Consultation. Geneva,
WHO Technical Report Series No 894, 2000.
27. Rudwaleit M, Landewe R, van der Heijde D, Listing J, Brandt J,
Braun J, et al. The development of Assessment of Spondy-
loArthritis international Society classification criteria for axial
spondyloarthritis (part I): classification of paper patients by ex-
pert opinion including uncertainty appraisal. Ann Rheum Dis
2000;68:770–776.
28. Reveille J, Witter J, Weisman M. Prevalence of Axial Spondy-
larthritis in the United States: Estimates From a Cross-Section-
al Survey. Arthritis Care Res 2012;64:905–910
29. Hukuda S, Minami M, Saito T, Mitsui H, Matsui N, Komatsub-
ara Y et al. Spondyloarthropathies in Japan: nationwide ques-
tionnaire survey performed by the Japan Ankylosing Spondyli-
tis Society. J Rheumatol 2001;28:554–559.
30. Boyer G, Templin D, Cornoni-Huntley J, Everett D, Lawrence
R, Heyse S et al. Prevalence of spondyloarthropathies in Alaskan
Eskimos. J Rheumatol 1994;21:2292–2297.
31. Van der Linden SM, Valkenburg HA, de Jongh BM, Cats A. The
risk of developing ankylosing spondylitis in HLA-B27 positive
individuals. A comparison of relatives of spondylitis patients
with the general population. Arthritis Rheum 1984;27:
241–249.
32. Gran JT, Husby G, Hordvik M. Prevalence of ankylosing
spondylitis in males and females in a young middle-aged pop-
ulation of Tromsø, northern Norway. Ann Rheum Dis
1985;44:359–367.
33. Braun J, Bollow M, Remlinger G, Eggens U, Rudwaleit M, Dis-
tler A, et al. Prevalence of spondylarthropathies in HLA-B27
positive and negative blood donors. Arthritis Rheum
1998;41:58–67.
34. Toussirot É. Diagnosis and Management of Late-Onset Spondy-
loarthritis: Implications of Treat-to-Target Recommendations.
Drugs Aging 2015;32:515–524.
35. Michelsen B, Fiane R, Diamantopoulos AP, Soldal DM, Hansen
IJW, Sokka T, et al. A Comparison of Disease Burden in Rheuma-
toid Arthritis, Psoriatic Arthritis and Axial Spondyloarthritis.
Zhang C, editor. PLOS ONE 2015;10:e0123582.
36. Rodríguez-Lozano C, Juanola X, Cruz-Martínez J, Peña-Ar-
rébola A, Mulero J, Gratacós J, et al. Outcome of an education
and home-based exercise programme for patients with anky-
losing spondylitis: a nationwide randomized study. Clin Exp
Rheumatol 2013;31:739–748.
37. Aytekin E, Caglar NS, Ozgonenel L, Tutun S, Demiryontar DY,
Demir SE. Home-based exercise therapy in patients with anky-
losing spondylitis: effects on pain, mobility, disease activity,
quality of life, and respiratory functions. Clin Rheumatol
2012;31:91–97.
38. Braun J, Van den Berg R, Baraliakos X, Boehm H, Burgos-Var-
gas R, Collantes-Estevez E, et al. 2010 update of the ASAS/EU-
LAR recommendations for the management of ankylosing
spondylitis. Ann Rheum Dis 2011;70:896–904.
39. Feldtkeller E, Lind-Albrecht G, Rudwaleit M. Core set of rec-
ommendations for patients with ankylosing spondylitis con-
cerning behavior and environmental adaptations. Rheumatol
Int 2013;33:2343–2349.
40. Raptopoulou A, Sidiropoulos P, Siakka P, Boki K, Drosos AA,
Aslanidis S, et al. Evidence-based recommendations for the
management of ankylosing spondylitis: results of the Hellenic
working group of the 3E Initiative in Rheumatology. Clin Exp
Rheumatol 2008;26:784–792.
41. Tobin A-M, Veale DJ, Fitzgerald O, Rogers S, Collins P, O’Shea
D, et al. Cardiovascular disease and risk factors in patients with
psoriasis and psoriatic arthritis. J Rheumatol 2010;37:
1386–1394.
42. Peters L, Van Eijk C, Smulders M, Serne E, Dijkmans C, van der
Horst-Bruinsma E, et al. Signs of accelerated preclinical
atherosclerosis in patients with ankylosing spondylitis. J
Rheumatol 2010;37:161–166.
43. Mathieu S, Motreff P, Soubrier M. Spondyloarthropathies: an
independent cardiovascular risk factor? Jt Bone Spine Rev Rhum
2010;77:542–545.
44. Van Halm V, Van Denderen J, Peters M, Twisk J, Van der Paardt
M, Van der Horst-Bruinsma I et al. Increased disease activity is
associated with a deteriorated lipid profile in patients with anky-
losing spondylitis. Ann Rheum Dis 2006;65:1473–1477.
45. Husni M, Merola J, Davin S. The psychosocial burden of psori-
atic arthritis. Semin Arthritis Rheum 2017;47:351–360.
46. Kotsis K, Voulgari P, Drosos A, Carvalho A, Hyphantis T. Health-
related quality of life in patients with ankylosing spondylitis: a
comprehensive review. Expert Rev Pharmacoecon Outcomes
Res 2014;14:857–872.
47. Ovayolu N, Ovayolu O, Karadag G. Health-related quality of
life in ankylosing spondylitis, fibromyalgia syndrome, and
rheumatoid arthritis: a comparison with a selected sample of
healthy ındividuals. Clin Rheumatol 2011;30:655–664.
48. Ramonda R, Marchesoni A, Carletto A, Bianchi G, Cutolo M,
Ferraccioli G et al. Patient-reported impact of spondyloarthri-
tis on work disability and working life: the ATLANTIS survey.
Arthritis Res Ther 2016;18:78.
